We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Methods Sought for Detecting Blood-Based Cancer Biomarkers

By LabMedica International staff writers
Posted on 01 Jul 2013
Two institutes will work on methods for detecting and tracking blood-based protein biomarkers for various cancers.

Thermo Fisher Scientific (Waltham, MA, USA) said that it would collaborate with the Newman-Lakka Institute (Boston, MA, USA) for personalized cancer care at Floating Hospital for Children at Tufts Medical Center on these methods. More...
The work will focus on applying the company's liquid chromatography-mass spectrometry equipment along with its mass spectrometry immunoassay technology to identify markers for breast and prostate cancer as well as tumor-associated blood vessel formation.

The collaboration's mass spec research will largely take place at Thermo Fishers' Biomarkers Research Initiatives in Mass Spectrometry (BRIMS; Cambridge, MA, USA) center, though an instrument will also be installed at the Genesis Research Institute laboratory adjacent to the Newman Lakka Institute.

"We hope to be able to provide oncologists with a panel of biomarkers that sense microscopic levels of tumor cells with a simple blood test," Charles Newman, president of the Newman-Lakka Cancer Foundation, said in a statement. "The goal is to develop diagnostic tools to make it possible for physicians to check off a panel of biomarkers when patients get regular checkups, so early detection of disease can facilitate effective treatment."

The approach of the Newman-Lakka Institute is different from other cancer centers that focus on identifying new tumor targets that can be used to develop new therapies. The Newman-Lakka Institute focuses on providing care to today's patients by using currently available targeted therapies that represent the best possible combination of agents for the individual patient. BRIMS provides applications assistance in biomarker discovery and verification.

Related Links:

Thermo Fisher Scientific
Newman-Lakka Institute
Thermo Fishers' Biomarkers Research Initiatives in Mass Spectrometry




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
HPV Test
Allplex HPV28 Detection
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.